A small circulating miRNAs signature predicts mortality and adverse cardiovascular outcomes in chronic hemodialysis patients.
cardiovascular events
hemodialysis
miRNA
mortality
Journal
Clinical kidney journal
ISSN: 2048-8505
Titre abrégé: Clin Kidney J
Pays: England
ID NLM: 101579321
Informations de publication
Date de publication:
May 2023
May 2023
Historique:
received:
03
11
2022
medline:
8
5
2023
pubmed:
8
5
2023
entrez:
8
5
2023
Statut:
epublish
Résumé
Chronic hemodialysis (HD) patients exhibit severe morpho-functional cardiac alterations, putting them at a high risk of death and adverse cardiovascular (CV) outcomes. Despite the fact that an unbalanced expression of various microRNAs (miRNAs) has been related to pathological cardiac remodeling and worse CV outcomes, scarce evidence exists on their role in this setting. We evaluated circulating levels of a selected miRNAs panel (30a-5p, 23a-3p, 451a and let7d-5p) in 74 chronic HD patients together with a thorough clinical and echocardiography assessment. Individuals were then prospectively followed (median 22 months). The primary endpoint was a composite of all-cause and CV mortality and non-fatal CV events. Circulating levels of all miRNAs were lower in HD patients as compared with healthy controls and independently correlated to the severity of cardiac dysfunction. miRNA 30a-5p, 23a-3p and 451a expression was even lower in 30 subjects (40.5%) reaching the composite endpoint ( Lower circulating levels of miRNA 30-5p, 23a-3p and 451a in HD patients may reflect cardiac abnormalities and predict a higher risk of worse clinical outcomes in the short mid-term. Future studies on larger HD populations are needed to generalize these findings.
Sections du résumé
Background
UNASSIGNED
Chronic hemodialysis (HD) patients exhibit severe morpho-functional cardiac alterations, putting them at a high risk of death and adverse cardiovascular (CV) outcomes. Despite the fact that an unbalanced expression of various microRNAs (miRNAs) has been related to pathological cardiac remodeling and worse CV outcomes, scarce evidence exists on their role in this setting.
Methods
UNASSIGNED
We evaluated circulating levels of a selected miRNAs panel (30a-5p, 23a-3p, 451a and let7d-5p) in 74 chronic HD patients together with a thorough clinical and echocardiography assessment. Individuals were then prospectively followed (median 22 months). The primary endpoint was a composite of all-cause and CV mortality and non-fatal CV events.
Results
UNASSIGNED
Circulating levels of all miRNAs were lower in HD patients as compared with healthy controls and independently correlated to the severity of cardiac dysfunction. miRNA 30a-5p, 23a-3p and 451a expression was even lower in 30 subjects (40.5%) reaching the composite endpoint (
Conclusions
UNASSIGNED
Lower circulating levels of miRNA 30-5p, 23a-3p and 451a in HD patients may reflect cardiac abnormalities and predict a higher risk of worse clinical outcomes in the short mid-term. Future studies on larger HD populations are needed to generalize these findings.
Identifiants
pubmed: 37151423
doi: 10.1093/ckj/sfad017
pii: sfad017
pmc: PMC10157794
doi:
Types de publication
Journal Article
Langues
eng
Pagination
868-878Informations de copyright
© The Author(s) 2023. Published by Oxford University Press on behalf of the ERA.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest with respect to the present work. The results presented in this paper have not been published previously in whole or part, except in abstract format.
Références
Med Sci Monit. 2019 May 27;25:3925-3932
pubmed: 31130720
Biomed Res Int. 2021 Oct 11;2021:9591177
pubmed: 34671680
Int J Mol Sci. 2022 Aug 12;23(16):
pubmed: 36012267
Clin J Am Soc Nephrol. 2009 Dec;4 Suppl 1:S79-91
pubmed: 19996010
J Clin Med. 2019 Jan 22;8(2):
pubmed: 30678250
Noncoding RNA. 2019 Mar 07;5(1):
pubmed: 30866581
Front Cell Dev Biol. 2019 Dec 03;7:314
pubmed: 31850348
PLoS One. 2012;7(12):e50926
pubmed: 23236408
J Transl Med. 2019 Apr 30;17(1):139
pubmed: 31039814
J Am Soc Echocardiogr. 2015 Jan;28(1):1-39.e14
pubmed: 25559473
Curr Top Med Chem. 2019;19(21):1918-1947
pubmed: 31393249
Nucleic Acids Res. 2019 Jan 8;47(D1):D155-D162
pubmed: 30423142
Int J Mol Med. 2020 Jul;46(1):83-96
pubmed: 32319531
Can J Physiol Pharmacol. 2022 Feb;100(2):167-175
pubmed: 35025607
J Physiol Biochem. 2022 Feb;78(1):257-269
pubmed: 34851490
EBioMedicine. 2018 Jun;32:172-181
pubmed: 29779700
PLoS One. 2017 Apr 17;12(4):e0175242
pubmed: 28414804
Heart Lung Circ. 2022 Feb;31(2):199-206
pubmed: 34088630
Kidney Int. 2011 Jul;80(1):112-8
pubmed: 21451461
ESC Heart Fail. 2022 Oct;9(5):3367-3379
pubmed: 35837763
JACC Clin Electrophysiol. 2020 Jan;6(1):70-79
pubmed: 31971908
J Am Soc Nephrol. 2015 Oct;26(10):2504-11
pubmed: 25733525
In Vitro Cell Dev Biol Anim. 2021 Sep;57(8):763-774
pubmed: 34608568
Lancet. 2017 Mar 25;389(10075):1238-1252
pubmed: 27887750
Int Urol Nephrol. 2022 Mar;54(3):575-588
pubmed: 34228259
Oncotarget. 2017 Jul 18;8(29):48145-48156
pubmed: 28624816
Sci Rep. 2018 Jun 29;8(1):9883
pubmed: 29959359
Cardiovasc Res. 2022 Jan 7;118(1):316-333
pubmed: 33135066
J Am Soc Nephrol. 2021 Feb;32(2):323-341
pubmed: 33478972
Theranostics. 2018 Feb 2;8(4):1180-1194
pubmed: 29464008
Sci Rep. 2021 Aug 2;11(1):15670
pubmed: 34341435
Nephrol Dial Transplant. 2011 Nov;26(11):3794-802
pubmed: 21891774
Circ J. 2011;75(3):703-9
pubmed: 21266788
J Biol Chem. 2017 Apr 7;292(14):6004-6013
pubmed: 27974462
In Vitro Cell Dev Biol Anim. 2020 Dec;56(10):866-877
pubmed: 33197036
Am J Physiol Renal Physiol. 2020 Feb 1;318(2):F315-F321
pubmed: 31813253
Biosci Rep. 2019 Aug 2;39(8):
pubmed: 31320543
Congest Heart Fail. 2013 Jul-Aug;19(4):E40-5
pubmed: 23615021
Mol Biol Rep. 2014 Jan;41(1):225-32
pubmed: 24197698
Int J Mol Sci. 2019 Mar 27;20(7):
pubmed: 30934671
Am J Physiol Cell Physiol. 2020 Jan 1;318(1):C94-C102
pubmed: 31618079